WIPI-dependent autophagy during neutrophil differentiation of NB4 acute promyelocytic leukemia cells. by Brigger, Daniel et al.
OPEN
WIPI-dependent autophagy during neutrophil
differentiation of NB4 acute promyelocytic leukemia
cells
D Brigger1,2, T Proikas-Cezanne3 and MP Tschan*,1,2,4
Members of the WD-repeat protein interacting with phosphoinositides (WIPI) family are phosphatidylinositol 3-phosphate (PI3P)
effectors that are essential for the formation of autophagosomes. Autophagosomes, unique double-membraned organelles, are
characteristic for autophagy, a bulk degradation mechanism with cytoprotective and homeostatic function. Both, WIPI-1 and
WIPI-2 are aberrantly expressed in several solid tumors, linking these genes to carcinogenesis. We now found that the
expression of WIPI-1 was significantly reduced in a large cohort of 98 primary acute myeloid leukemia (AML) patient samples
(complex karyotypes; t(8;21); t(15,17); inv(16)). In contrast, the expression of WIPI-2 was only reduced in acute promyelocytic
leukemia (APL), a distinct subtype of AML (t(15,17)). As AML cells are blocked in their differentiation, we tested if the expression
levels of WIPI-1 and WIPI-2 increase during all-trans retinoic acid (ATRA)-induced neutrophil differentiation of APL. According to
the higher WIPI-1 expression in granulocytes compared with immature blast cells, WIPI-1 but not WIPI-2 expression was
significantly induced during neutrophil differentiation of NB4 APL cells. Interestingly, the induction of WIPI-1 expression was
dependent on the transcription factor PU.1, a master regulator of myelopoiesis, supporting our notion that WIPI-1 expression is
reduced in AML patients lacking proper PU-1 activity. Further, knocking down WIPI-1 in NB4 cells markedly attenuated the
autophagic flux and significantly reduced neutrophil differentiation. This result was also achieved by knocking down WIPI-2,
suggesting that both WIPI-1 and WIPI-2 are functionally required and not redundant in mediating the PI3P signal at the onset of
autophagy in NB4 cells. In line with these data, downregulation of PI3KC3 (hVPS34), which generates PI3P upstream of WIPIs,
also inhibited neutrophil differentiation. In conclusion, we demonstrate that both WIPI-1 and WIPI-2 are required for the PI3P-
dependent autophagic activity during neutrophil differentiation, and that PU.1-dependent WIPI-1 expression is significantly
repressed in primary AML patient samples and that the induction of autophagic flux is associated with neutrophil differentiation
of APL cells.
Cell Death and Disease (2014) 5, e1315; doi:10.1038/cddis.2014.261; published online 3 July 2014
Macroautophagy (hereafter referred to as autophagy), or
cellular self-digestion, is: (a) involved in the maintenance of
cellular homeostasis, (b) responsible for a constitutive
turnover of cytoplasmic material and long-lived proteins that
are either damaged or functionally redundant, (c) highly
conserved, and (d) linked to a variety of diseases including
neurodegenenerative disorders and cancer.1–3 The ubiquitin–
proteasome pathway, on the other hand, rather participates in
the degradation of short-lived proteins.4 Autophagy mainly
consists of four steps and follows a hierarchical ordered
recruitment of autophagy related (ATG) proteins to the
phagophore assembly site (PAS). Firstly, the initiation step
critically involves the ULK1 complex, which regulates the
following nucleation step by activating phosphatidylinositol
3-kinase class III (PI3KC3) kinases ultimately resulting in the
formation of an autophagosome precursor, called phago-
phore. Further steps include the activity of two ubiquitin-like
conjugation systems, and the product LC3-PE (or LC3-II)
which is required for phagophore elongation and closure to
generate an autophagosome.5
During the nucleation step, PI3KC3 is acting in concert with
Beclin 1, VPS15 and ATG14L to produce PI3P. This PI3P
signal is essential for autophagosome formation as evidenced
by the fact that the use of PI3K inhibitors (wortmannin, 3-MA,
LY29002) at concentrations preferentially blocking PI3KC3-
abolished autophagy6–8 (reviewed in Petiot et al.9). Transduction
of the PI3P signal occurs via specific PI3P-binding effectors,
including the FYVE-domain protein DFCP110 and the
WD-repeat protein interacting with phosphoinositides (WIPI)
beta-propeller protein family.11 The human WIPI family
consists of four members (WIPI-1 to WIPI-4) with different
isoforms.11 To date, human WIPI-1, WIPI-2 and WIPI-4 proteins
were functionally associated with the process of auto-
phagy.11–14 WIPI proteins function as autophagic PI3P
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effector proteins with autophagosomal membrane binding
capacity,15 and thereby translocate from the cytosol to the
forming PAS. They subsequently become membrane proteins
of autophagosomal membranes, visible by fluorescent micro-
scopy as punctate structures.15
Acute myeloid leukemia (AML) is characterized by a block
of myeloid differentiation at different stages and represents
the most common acute leukemia in adults.16 Current
differentiation and cytotoxic therapies for AML, with the
exception of a few subgroups with favorable genetic disease,
need to be improved. Recently, we and others published that
autophagy is essential for differentiation therapy of APL
patients,17–21 a disease characterized by the translocation
t(15;17) resulting in the expression of the oncogenic PML–
RARA fusion protein and an accumulation of promyelocytic
cells. Nevertheless, data on the molecular mechanisms
underlying this myeloid differentiation-associated autophagy
are scarce and further investigations of this particular
autophagic pathway are warranted.
Here, we demonstrate that PI3P-dependent WIPI-mediated
autophagy is required for neutrophil differentiation
of AML cells. We found that WIPI mRNA expression is
significantly repressed in clinical AML samples being
associated with an immature myeloid differentiation pheno-
type. Genetically imparing WIPI or PI3KC3 but not Beclin 1
function resulted in significantly attenuated neutrophil
differentiation of APL cells. Our data provide evidence that
WIPI-mediated autophagy is critical for cellular myeloid
leukemia differentiation and is compromised in AML.
Results
Aberrant WIPI expression in primary AML patient
samples and PU.1-dependent induction of WIPI-1
expression during neutrophil differentiation of APL
cells. On the basis of the crucial role of WIPI proteins as
PI3P effectors in the process of autophagy11–13,15 and the
initial findings, that all human WIPI genes are aberrantly
and differentially expressed in a variety of solid tumors,11
we quantified WIPI-1 and WIPI-2 gene expression in clinical
AML patient samples. We found that WIPI-1 mRNA
abundance was significantly reduced in our cohort of AML
patients (n¼ 98) when compared with the expression of
WIPI-1 in healthy granulocytes (n¼ 13; Figure 1a, left
panels). In more detail, WIPI-1 message was downregulated
in complex karyotype (n¼ 24), t(8,21) (n¼ 20), t(15;17)
(n¼ 20) and inv(16) (n¼ 16) AML subtypes but not in normal
karyotype AML (n¼ 18; Figure 1a, right panels). In contrast,
WIPI-2 mRNA expression was only significantly inhibited
in APL patients (t(15;17)), a distinct AML subtype
(Supplementary Figure 1a). Moreover, WIPI-1 was threefold
higher expressed in healthy granulocytes when compared
with normal CD34þ progenitor cells (Figure 1a, left panels),
whereas WIPI-2 was equally expressed in both of these cell
populations (Supplementary Figure 1a). In summary, we
found a positive association between low WIPI-1 expression
and an immature myeloid phenotype.
To functionally evaluate the role of both WIPI-1 and WIPI-2 in
ATRA-induced neutrophil differentiation of myeloid leukemia
cells, we used NB4 APL cells as a model. NB4 cells are
differentiated towards neutrophil-like cells by administration of
ATRA. In line with higher WIPI-1 expression in mature
neutrophils when compared with AML blast or CD34þ
progenitor cells (Figure 1a), ATRA treatment of NB4 cells
resulted in a significant three and fourfold upregulation of WIPI-
1 mRNA at day 4 and 6, respectively (Figure 1b, upper panel).
Importantly, WIPI-1 mRNA levels did not change in the ATRA-
resistant NB4-R2 cells (Figure 1b, lower panel) indicating that
the upregulation of WIPI-1 expression is not due to a stochastic
stress response to ATRA administration. Lastly, WIPI-2 mRNA
levels did neither change during neutrophil differentiation of NB4
cells nor in NB4-R2 cells (Supplementary Figure 1b).
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Figure 1 Significantly decreased WIPI-1 mRNA expression in primary AML patient samples and increase in WIPI-1 expression upon ATRA treatment of NB4 APL cells
was detected. (a) WIPI-1 mRNA levels of granulocytes from healthy donors and AML patient samples were measured using qPCR. Data represent log2 expression levels and
were normalized to the expression levels of the two housekeeping genes HMBS and ABL. For better readability, we multiplied the results by ( 1) and excluded Ct values
higher than 40 (DCt¼ 40CtWIPI-1 (Mean CtHMBS and CtABL1)  ( 1)). (b) mRNA levels of WIPI-1 expression was measured in control, and ATRA-treated NB4,
NB4-R2 APL cell lines at day 4 using qPCR. Values were normalized to the housekeeping gene HMBS and given as n-fold mRNA expression relative to the control of day 4.
(c, d) Increase in endogenous WIPI-1 puncta was detected using confocal microscopy and was further quantified using ImageJ software. (e) PI3P:WIPI-1 binding assay of cell
lysates from NB4 cells treated with 1mM ATRA for 6 days. Each membrane was loaded with equal total protein lysate. M.W.U, *Po0.05. **Po0.01, ***Po0.001. M.W.U,
Mann–Whitney U-test
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To monitor the autophagic status, we assessed the
localization of endogenous WIPI-1 protein in NB4 cells during
neutrophil differentiation by immunocytochemistry. Using this
imaging method, the presence of fluorescent WIPI-1 puncta
reliably reflects the formation of autophagosomal mem-
branes.15 Indeed, a significant increase of WIPI-1 puncta
per cell was measured upon ATRA-induced neutrophil
differentiation (Figure 1c and d). As WIPI-1 specifically binds
to PI3P,15 we asked whether increased WIPI-1 expression
upon ATRA treatment (Figure 1b, upper panel) would result in
a higher proportion of WIPI-1 protein binding to PI3P. Indeed,
a phospholipid–protein overlay assay with native cell extracts
revealed that endogenous WIPI-1 protein from ATRA-treated
NB4 APL cells bound more prominently to immobilized PI3P
when compared with untreated cells (n¼ 3, a representative
result is provided in Figure 1e). Satisfactory, this result also
confirmed that endogenous WIPI-1 extracted from NB4 APL
properly binds to PI3P.
To test if low WIPI-1 expression in immature AML blasts
might be attributed to aberrant transcriptional regulation by
myeloid transcription factors, we analyzed the 5.8 kb genomic
region upstream of the WIPI-1 transcriptional start site for
putative binding sites of the key myeloid transcription factor
PU.1 using MatInspector. We identified 4 putative PU.1
binding sites (A–D) in the 50-promoter region of WIPI-1
(Figure 2a). By using chromatin immunoprecipitation and anti-
PU.1 antibodies, we found binding of PU.1 to all 4 PU.1
binding sites (A–D) in the 50-promotor of human WIPI-1
(Figure 2b). In order to show PU.1-dependent regulation of
WIPI-1 expression, we either knocked down or over-
expressed PU.1 in NB4 APL cells. Knocking down PU.1
impaired induction of WIPI-1 gene expression upon ATRA
treatment (Figure 2c), whereas tamoxifen treatment of the
inducible PU.1-ER fusion protein led to a significant twofold
induction of WIPI-1 expression (Figure 2d).
Together, we found that PU.1 regulates WIPI-1 expression
during neutrophil differentiation.
Inhibiting WIPI-1 or WIPI-2 significantly attenuates
neutrophil differentiation. We addressed the question
whether or not WIPI-1 is required for ATRA-induced
neutrophil differentiation by using lentivirally delivered
shRNA targeting WIPI-1. Clearly, knocking down WIPI-1
impaired neutrophil differentiation as evidenced by signifi-
cantly reduced CD11b protein and CEBPE mRNA levels,
both bona fide markers for neutrophil differentiation of AML
cell lines (Figures 3a–d, top row panels). Interestingly,
knocking down WIPI-2 also resulted in impaired neutrophil
differentiation (Figures 3a–d, second row panels). These
results demonstrate that the neutrophil differentiation
depends on WIPI function.
To further address the PI3P-dependent initiation of auto-
phagy during APL differentiation, we investigated if lentivirally
delivered shRNA targeting of PI3KC3 or its regulatory subunit
Beclin 1 (BECN1) interferes with ATRA-induced neutrophil
differentiation. Knocking down PI3KC3 resulted in drastically
impaired neutrophil differentiation (Figures 3a–d, third row
panels). Accordingly, inhibiting PI3P production using
the small compound PI3K inhibitor LY294002 that inhibits
the formation of WIPI-1 puncta,13 also reduced the abun-
dance of CD11b, marking NB4 differentiation (Supplementary
Figure 2). However, inhibiting Beclin 1 did not affect ATRA-
induced neutrophil differentiation as similar CD11b and
CEBPE levels in NB4 control and Beclin 1-knockdown cells
were found (Figures 3a–d, fourth row panels). This indicates
that PI3P-dependent WIPI function at autophagy initiation is
required for neutrophil differentiation of NB4 cells but that the
regulatory subunit of the PI3KC3 complex Beclin 1 might not
be involved in PI3P production in this cell type.
Importantly, we also tested if knocking down WIPI-1, WIPI-2,
PI3KC3 or Beclin 1 affected neutrophil function using a
nitroblue tetrazolium (NBT) assay that measures the produc-
tion of reactive oxygen species (Figure 3e). Seventy-two
percent of control cells transduced with non-targeting shRNAs
reduced colorless NBT into intracellular dark deposits after
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96 h of ATRA treatment (Figure 3e). Only 39% of WIPI-1 and
50% of WIPI-2 APL knockdown cells stained NBT positive
(Figure 3e, quantification on the right). Similarly, knocking
down PI3KC3 attenuated neutrophil function, whereas inhibit-
ing Beclin 1 did not influence NBT reduction upon neutrophil
differentiation (Figure 3e). This result further underlines that
WIPI-1, WIPI-2 and PI3KC3 but not Beclin 1 participate in
ATRA-induced neutrophil differentiation and function of
myeloid leukemia cells.
Furthermore, direct comparison of relative WIPI-1 and
WIPI-2 transcript levels revealed that WIPI-2 (90–99%) is
expressed more in undifferentiated and differentiated NB4
APL cells than WIPI-1 (1–10%), which suggests a rate-limiting
role of WIPI-1 during ATRA-induced neutrophil differentiation
of NB4 cells (Figure 3f).
To control whether Beclin 1-knockdown cells are
autophagy-competent, we measured LC3 puncta formation
upon both short-term starvation and ATRA treatment.22,23 As
expected, knocking down Beclin 1 inhibited starvation-
induced autophagy (Supplementary Figure 3a, black bars);
however, knocking down Beclin 1 did not affect ATRA-
induced autophagy (Supplementary Figure 3a, white bars).
Moreover, we employed a biochemical standard method to
determine the turnover of long-lived proteins by autophagy
and measured the proteolysis of radiolabeled proteins in
Beclin 1-knockdown cells.23 The proteolysis in Beclin 1-
knockdown cells under basal conditions was not significantly
decreased upon bafilomycin A1 treatment whereas ATRA-
treated samples showed significantly reduced proteolysis
upon combined treatment with bafilomycin A1 suggesting that
basal but not ATRA-induced autophagy requires Beclin 1.
Consistent with the role of Beclin 1 in starvation-induced
autophagy, Beclin 1-knockdown cells did not show increased
proteolysis during starvation compared to control cells
(Supplementary Figure 3b), supporting a function for
Beclin 1 in canonical autophagy found during starvation
or during basal conditions but not during ATRA treatment.
Of note, Beclin 1-independent entries to autophagic seques-
tration have been reported.5
WIPI-1- and WIPI-2-dependent autophagy during
neutrophil differentiation. Next, we asked if the involve-
ment of the PI3P effector proteins WIPI-1 and WIPI-2 in
neutrophil differentiation can be attributed, at least in part, to
their role in autophagy. To address this question, we
analyzed the autophagic flux in NB4 WIPI-1 and WIPI-2
knockdown cells by LC3-II western blotting in the presence or
absence of the lysosomal inhibitor bafilomycin A1. We found
markedly decreased amounts of endogenous, lipidated
LC3-II protein after 4 days of ATRA treatment in combination
with bafilomycin A1 treatment indicating reduced autophagic
levels in these knockdown cells compared with control cells
(Figure 4a). Further, we expressed EGFP-Cherry-tagged
LC3 in NB4 WIPI-1 as well as WIPI-2 knockdown cells.
Intracellular localization of EGFP-Cherry-LC3 visualizes
autophagosomal membranes following LC3 lipidation.24
In general, upon both autophagy inductions (e.g., starvation)
and inhibition (e.g., bafilomycin A1) an increase in LC3
puncta formation is observed. Using EGFP-Cherry-LC3
however, induction and inhibition of autophagy can be
distinguished. As the EGFP signal is more sensitive to the
acidic and/or proteolytic conditions of the lysosomal lumen
compared with the Cherry signal, an increase in red LC3
puncta (EGFP /Cherryþ ) per cell reflects active auto-
phagic flux, and a decrease in colocalizing EGFPþ /Cherryþ
signals (yellow puncta) reflects the inhibition of autophagy.
Using control shRNAs, we detected an accumulation of
EGFP /Cherryþ LC3 puncta (red) at day 4 of ATRA
treatment when compared with untreated cells indicating
increased autophagic flux. An accumulation of yellow LC3
puncta was detected after blocking autophagosomal degra-
dation (bafilomycin A1, Baf A1) during ATRA treatment
(Figure 4b). In contrast, when either WIPI-1 or WIPI-2 were
knocked down by lentiviral shRNA targeting, the acculuma-
tion of EGFP /Cherryþ LC3 (red) puncta upon ATRA
treatment was attenuated as well as of EGFPþ /Cherryþ
(yellow) LC3 puncta formation upon ATRA and bafilomycin
A1 co-treatment (Figure 4b). Moreover, the turnover of
long-lived proteins was measured in WIPI-1 and WIPI-2
knockdown cells. We found that the proteolysis of long-lived
14C-labeled proteins was significantly increased after 4 days
of ATRA treatment in NB4 SHC002 control cells. In NB4
WIPI-1 and WIPI-2 knockdown cells, however, this increase
was significantly abolished (Figure 4c and Supplementary
Figure 4a). Furthermore, inhibiting the WIPI-1 upstream
regulator PU.1 resulted in significantly reduced long-lived
protein degradation as well (Figure 4d and supplementary
Figure 4b). As knocking down PU.1 attenuates ATRA-mediated
differentiation, we employed ATRA-resistant NB4-R2 cells to
test if decreased autophagy seen in PU.1-knockdown cells is
mainly due to the attenuated differentiation potential in these
cells. Autophagic flux as determined by LC3-II protein
abundance in the presence of the lysosomal inhibitor
bafilomycin A1 was inhibited in ATRA-resistant NB4-R2 cells
(Supplementary Figure 4c). These data clearly show that
induction of autophagic flux is associated with neutrophil
differentiation of APL cells.
In order to further determine autophagic levels during
ATRA-induced differentiation in Beclin 1-knockdown cells,
we perfomed long-lived protein degradation and EGFP-
Figure 3 Impaired neutrophil differentiation in NB4 WIPI-1, WIPI-2, PI3KC3 but not in BECN1 knockdown cells. (a) SHC002, shWIPI-1, shWIPI-2, shPI3KC3 and
shBECN1 expressing NB4 cells were differentiated for 4 days and knockdown efficiency was measured by qPCR. (b) Neutrophil differentiation was assessed by measuring
CD11b surface expression with FACS analysis, a representative CD11b histogram is shown. (c) Bar graphs of the median fluorescence intensity of three independent
experiments are shown. (d) CEBPE mRNA expression was measured by qPCR in SHC002, shWIPI-1, shWIPI-2, shPI3KC3 and shBECN1 expressing NB4 cells upon 1 mM
ATRA treatment after 4 days. (e) NBT assay was performed at day 4 in SHC, shWIPI-1, shWIPI-2, shPI3KC3 and shBECN1 NB4 APL cells and NBT-positive cells were
quantified from two independent experiments done in duplicate. (f) Relative transcript abundance for WIPI-1 and WIPI-2 was calculated as described in.12 M.W.U, *Po0.05.
**Po0.01, ***Po0.001. M.W.U, Mann–Whitney U-test
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Cherry-LC3 tandem assays in the respective knockdown cells
at day 4. Inhibiting Beclin 1 did not significantly decrease
proteolysis of long-lived proteins and no differences for
EGFP-Cherry-LC3 puncta formation were observed in Beclin
1 knockdown compared with control cells after 4 days of ATRA
treatment (Supplementary Figure 4d and e). On the other
hand, NB4 PI3KC3 knockdown cells showed a clear
trend (P¼ 0.07) towards a reduction of autophagic flux
during APL differentiation when compared with control cells
(Supplementary Figure 4e). To exclude that increased cell
death causes the differences in the flux assays, we performed
Annexin V and propidium iodide (PI) staining. We observed
similar increased cell death levels in Beclin 1, WIPI-1
and PI3KC3 knockdown as compared with control
cells (Supplementary Figure 4f). Thus, we exclude that
differences in cell death among the different autophagy
knockdown cells are responsible for the different autophagic
flux following ATRA treatment in Beclin 1 versus the other
knockdown cells.
In summary, blocking WIPI-1 or WIPI-2 and PI3KC3 but
not Beclin 1 significantly impairs ATRA-induced neutrophil
differentiation at least in part due to impaired autophagy.
Discussion
Deregulation of human WIPI expression was so far only
described in a variety of solid cancers, including kidney,
pancreatic, skin, uterine and ovarian cancer.11 We now add
AML to the list of cancers with aberrant low WIPI expression.
We found that WIPI-1, but not WIPI-2 with the exception of
APL, is significantly downregulated in AML patients when
compared with mature, healthy neutrophils. Hence,
decreased WIPI-1 levels might contribute to the immature
myeloid phenotype of AML blasts. Supporting this
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observation, WIPI-1 but not WIPI-2 levels were significantly
upregulated during neutrophil differentiation of APL cells.
However, the inhibition of WIPI-1 as well as of WIPI-2
significantly impaired neutrophil differentiation. This might
be explained by the much higher relative WIPI-2 levels
compared with WIPI-1 in NB4 APL cells that are already
sufficient to allow differentiation. High WIPI-2 expression in
these cells may indicate additional functions of WIPI-2 also in
non-differentiating conditions.12 Moreover, our results indicate
that WIPI-1 and WIPI-2 are functionally not redundant during
ATRA-induced granulocytic differentiation, thereby supporting
the initial observation that all WIPI family members function as
PI3P effectors but have different roles in autophagy and
cancer.11,25
The analysis of the transcriptional regulation of ATG genes
is still in its infancy. Several studies reported that the p53
family of tumor suppressors or E2F transcription factors
regulate expression of several ATG genes.26,27 Recently,
GATA-1 was identified as the first hematopoietic transcription
factor regulating the LC3/ATG8 family of autophagy genes
that mediate mitochondrial clearance during erythropoiesis.28
Here, we identify WIPI-1 as a new target of PU.1, an essential
transcription factor for neutrophil differentiation that is
functionally impaired in AML. Further supporting PU.1-
mediated transcriptional regulation of WIPI-1, Wang et al.29
described PU.1 binding to a site 20 kb upstream of WIPI-1
transcriptional start in the course of a global survey of
PU.1 binding sites in U937 AML cells. As GATA-1, a functional
PU.1 agonist during erythroid differentiation, interacts
with PU.1, it is likely that GATA-1 and PU.1 cooperate in
controlling ATG gene expression in hemtatopoietic cells.30,31
As data from Trocoli et al.19 suggest a Beclin 1-independent
autophagy mechanism during ATRA-induced granulocytic
differentiation, we asked whether autophagy required for
ATRA-induced granulocytic differentiation depends on
canonical PI3P generation as well as their PI3P effector
proteins. We have shown that PI3P effector proteins (WIPIs)
contribute to ATRA-induced granulocytic differentiation.
In addition, we showed that inhibition of WIPI-1 and
WIPI-2 reduced autophagy flux during ATRA-induced
neutrophil differentiation suggesting that these proteins
support neutrophil differentiation, at least in part, by activating
autophagy. Moreover, WIPI-1 puncta are increased upon
ATRA administration indicating that WIPI-1 binds to auto-
phagosomal membranes as described for canonical
autophagy11,32 and not just increases LC3 lipidation as
described for resveratrol-mediated non-canonical autophagy.13
Further, we earlier demonstrated that differentiation-
associated autophagy depends on ATG5 puncta formation21
and now we show that WIPI-1/WIPI-2 function upstream of the
ATG5-LC3 axis as described by others.13,33 If WIPI-2 acts
upstream of WIPI-1 or vice versa as described,12 it is still
under discussion and should rather be investigated in
starvation-induced autophagy. In conclusion, we identify both
PI3P effector proteins, WIPI-1 and WIPI-2 as positive
regulators of neutrophil differentiation in APL cells.
Canonical autophagy is mainly characterized by the
generation of the Beclin 1/PI3KC3 complexes and requires
the generation of the phosphatidolinositol 3-phosphat (PI3P)
signaling lipid34 (reviewed in Burman et al.35). We clearly
demonstrate that neutrophil differentiation of APL cells
depends on PI3P using pharmacological (LY294002) and
genetic inhibition of PI3KC3. Both PI3P inhibition methods
resulted in the same phenotype regarding differentiation and
autophagy, which is consistent with previous published data.36
This further underlies our hypothesis that PI3P, mainly but not
exclusively originating from PI3 kinases class III,37 is crucial for
ATRA-induced neutrophil differentiation in an autophagy-
dependent manner.
Beclin 1, although enzymatically inert, supports the
autophagic process by regulating PI3KC3-dependent gen-
eration of PI3P.34 Interestingly, Beclin 1 neither impaired
neutrophil differentiation nor autophagy flux for short-term
treatment as assessed by measuring endogenous LC3
puncta. On the basis of our additional PI3KC3, WIPI-1 and
WIPI-2 knockdown data showing impaired neutrophil differ-
entiation due to attenuated autophagy, it is tempting to
speculate that the initiation of ATRA-induced granulocytic
differentiation of APL cells follows a non-canonical, Beclin
1-independent, autophagy pathway. In addition, it has been
reported that ATRA in combination with everolimus could
enhance growth arrest and differentiation in NB4 and
HL60 cells further illustrating that autophagy contributes to
ATRA-induced differentiation.38
In summary, our data clearly support an important role for
autophagy in APL differentiation, which is dependent on the
PI3P-WIPI-1/2-LC3 axis. Lastly, the newly discovered PI3P-
WIPI-1/2-LC3 pathway operative in neutrophil differentiation
of APL cells should be taken into consideration when
designing therapeutic strategies that target autophagy in
cancer treatments.
Material and Methods
Primary patient samples. A cohort of 98 AML patient samples
were enrolled on HOVON/SAKK (Dutch-Belgian Hematology-Oncology/ Swiss
Group for Clinical Cancer Research Cooperative group) protocols -04, -04A, -29,
and -42.39–43 All patients provided written informed consent in accordance with the
Declaration of Helsinki. Bone marrow aspirates or peripheral blood samples
were taken at diagnosis. Blasts and mononuclear cells were purified by Ficoll-
Hypaque (Nygaard, Oslo, Norway) centrifugation and cryopreserved. The AML
samples contained 80–100% blast cells after thawing, regardless of the blast
count at diagnosis. Mutational analyses and classification were performed
as described previously.44 Please see Supplementary Table 1 for patient
characteristics.
Cell lines and culture conditions. The human acute promyelocytic
leukemic (APL) cell lines NB4 and its ATRA-resistant NB4-R2 subclone45 were
kindly provided by B.E.Torbett. Cell lines were cultured in RPMI-1640 medium
(Sigma-Aldrich, Buchs, Switzerland) supplemented with 10% fetal bovine serum,
50 U/ml penicillin and 50mg/ml streptomycin in humidified atmosphere containing
5% CO2 at 37 1C. Differentiation of NB4 cells was induced with 1mM ATRA for
4 to 6 days. Successful neutrophil differentiation was assessed by FACS analysis
of CD11b protein or quantitative RT-PCR (qPCR) for CEBPE mRNA expression.
Functional differentiation was tested by the NBT-reduction assay46 performed as
follows: cells were washed with PBS and treated with NBT/PMA for 20 min at
37 1C, 5% CO2. After incubation, cells were transferred to coated glass slides by
cytospin and counterstained with Safranin O. NBT-positive cells were counted.
At least 200 cells were scored for each determination from two independent
experiments done in duplicate. Data was expressed as the percentage of
NBT-positive cell number relative to viable cell number. Cell death in SHC002 or
shWIPI-1, shPI3KC3 and shBECN1-transfected cells upon ATRA treatment was
assessed using AnnexinV/PI staining and flow cytometry. The isolation of primary
neutrophils was performed using polymorphprep (AXIS-SHIELD, Axon Lab,
WIPI-dependent autophagy in AML
D Brigger et al
7
Cell Death and Disease
Baden, Switzerland). Cells were layered carefully over Polymorphprep and
centrifuged for 40min at 400 g at room temperature. Primary neutrophils were
harvested and RNA was isolated as described below.
TaqMan low-density array and real-time qRT-PCR (qPCR). RNA
extraction, RT-PCR, low-density array measurements as well as data analysis
were performed as described.47 Gene Expression Assays for WIPI-1, WIPI-2,
PI3KC3, BECN1 and CEBPE used in a 96-well format on the ABI 7500 Sequence
detection system were Hs00215872_m1, Hs00255379_m1, Hs00176908_m1,
Hs00186838_m1 and Hs00357657_m1, respectively (Applied Biosystems,
Rotkreuz, Switzerland). HMBS primer and probes have been described
previously.48
Autophagy assays. ATRA-induced autophagy was blocked using bafilomycin
A1 (BML-CM110, Enzo Life Sciences, Lausen, Switzerland) 100 nM or 200 nM.
LY294002 (L9908, Sigma-Aldrich) was used at a concentration of 10mM.
Starvation (EBSS, Sigma-Aldrich (E2888)) was induced for 5 h before analysis.
Protein degradation assay was performed as follows. Cells were treated with or
without ATRA and bafilomycin A1 for 4 days. 0.3mCi 14C-Valine (L-(U-14-
C)Valine, Code CFB.75, Amersham) per ml/well was added after 2 days of ATRA
treatment. Addition of bafilomycin A1 was performed 24 h before analysis. At day
4, assay was performed as described in.49 Short-term assays were performed as
follows: cells were incubated for 2 days with 0.3 mCi 14C-Valine per ml/well. At day
2, assay was performed as described in.49
Western blotting. Whole cell extracts were prepared using RIPA or
alternatively in lysis buffer containing aminocaproic acid, 50mM Bis-Tris,
0.5 mM EDTA, 1% Triton-X100, supplemented with proteinase inhibitor cocktail
(complete, Roche Diagnostics, Rotkreuz, Switzerland). Eighty to 120 mg of total
protein was separated on a 12% SDS-polyacrylamide gel and transferred to
membrane. Blots were incubated with primary antibody in TBS 0.05% Tween-20/
3% BSA overnight at 4 1C, washed and incubated with IRDye- coupled secondary
anti-mouse or anti-rabbit antibodies for 1 h at room temperature protected from
light. Primary antibodies used were anti-LC3B (NB600-1384; Novus Biologicals
(LuBioScience), Luzern, Switzerland), anti-WIPI-1 antiserum11 and anti-GAPDH
(MAB374; Millipore, Zug, Switzerland). Secondary antibodies were Infra-RedDye
680LT-conjugated Goat (polyclonal) Anti-Mouse IgG (Hþ L), (LICOR) (1 : 10 000)
and Infra-RedDye 800CW-conjugated Goat (polyclonal) Anti-Rabbit IgG (Hþ L)
(LI-COR). Data were analyzed using the LI-COR Odyssey Infra-Red Imager
(Odyssey, Bad Homburg, Germany).
Phospholipid–protein overlay assay. Aminocaproic acid, 50mM Bis-
Tris, 0.5 mM EDTA, 1% Triton-X 100 supplemented with proteinase inhibitor
cocktail (complete, Roche Diagnostics)) supplemented with TBSþ 0.5% Tween in
3% BSA were used to overlay membrane-immobilized phospholipid membranes
(Echelon Biosciences Inc., Salt Lake City, UT, USA; P-6001). LICOR detection of
bound WIPI-1 protein using anti-WIPI-1 antiserum was performed as described
above.
ChIP assay. Chromatin immunoprecipitation assay (ChIP) was performed as
described.40 Genomic regions containing putative PU.1 binding sites were
amplified by PCR using the following primers: site A; forward 50-TGGT
TGGGTGCCATGAATGACCA-30 and reverse 50-TGCACAGGGCATTCACAG
GGG-30, site B; forward 50-AGCAACCCAATGGGCTTCCCCT-30 and reverse
50-GGAAGGGGGAGGGGCAGGGA-30, site C; forward 50-ACTGGACAGCAATG
CCTGAAAACA-30 and reverse 50-TGGCCAGGGTGTGCAGAACAAA-30, site D;
forward 50-GCTGCGGATCGGATAGGTCTTGT-30 and reverse 50-TGACGGAGCT
GGAAGGTGGGG-30. In addition, an unrelated sequence in the GAPDH gene was
used as a negative control.50
Generation of stable knockdown cells and EGFP-Cherry-LC3
expressing cells. pLKO.1 lentiviral vectors expressing small hairpin
(sh)RNAs targeting WIPI-1, WIPI-2, PI3KC3 and BECN1 or a non-targeting
shRNA control (SHCOO2) were purchased from Sigma-Aldrich. A lentiviral vector
expressing EGFP-Cherry-LC3 was provided by Dr. MS Soengas. Lentiviral
production and transduction of NB4 cells was done as described.51 EGFP-Cherry-
LC3 NB4 cells with WIPI-1, WIPI-2 and BECN1 knockdown were generated by
serial transduction with both lentiviral vectors described above. Transduced cell
populations were selected for 4 days using 1.5mg/ml puromycin. qPCR was
performed to evaluate knockdown efficiency in NB4 WIPI-1, WIPI-2 and BECN1
knockdown cells, whereas western blotting was employed for demonstration for
beclin 1 inhibition. To generate PU.1-inducible cells, the pCl10A1 retroviral
packaging plasmid and the pBabe-PUER-puro (kindly provided by Dr. H Yoshida)
were co-transfected into 293T cells. Cell culture medium was removed after 1 day
and cells were incubated for 2 min with PBS/15% glycerol. PBS/15% glycerol was
replaced by fresh medium. Viral supernatants were harvested 48 h later. NB4 cells
were transduced for 24 h in the presence of 8 mg/ml polybrene. Transduced NB4
cell populations were selected with 1.5mg/ml puromycin for 4 days.
Fluorescence microscopy. EGFP-Cherry-LC3 expressing NB4 cells were
fixed with 2% paraformaldehyde washed with PBS (0.5% of Glycin). Subsequently,
cells were placed on a poly-L-lysine coated cover glass and mounted in
Fluorescence Mounting Medium (S3032; DAKO, Baar, Switzerland). Images were
taken on a confocal microscope at  60 magnification for puncta assay and on a
fluorescence microscope for the NBT assay.
Immunofluorescence microscopy. Cells were fixed with 2% para-
formaldehyde washed with PBS (0.5% of Glycin). Subsequently, cells were placed
on a poly-L-lysine-coated cover glass permeabilized with triton. Alternatively, cells
were fixed with ice-cold methanol for 4min after cytospun and then washed with
PBS (0.5% of Glycin). Incubation of anti-WIPI-1 and anti-LC3B antibody for 1 h at
room temperature followed by three washing step with PBS-T. Cells were
incubated with the second antibody (111-096-045, Jackson Immuno Research,
Suffolk, UK) for 1 h at room temperature. Prior mounting in Fluorescence Mounting
Medium (S3032; DAKO) cells were washed three times with PBS-T. Images were
taken on a confocal microscope at  60 magnification.
Statistical analysis. Nonparametric Mann–Whitney U-tests were applied to
compare the difference between two groups using the program GraphPad Prism 4
(Graph Pad Software, San Diego, CA, USA). P-valueso0.05 were considered to
be statistically significant.
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